In development: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Expected publication date

Expected publication date

Area of interest

Area of interest

Type

Type

Guidance programme 1 selected

Guidance programme

Showing 11 to 20 of 294

TitleTypeExpected publication date
Artificial intelligence (AI) technologies to assist histopathology for breast cancer diagnosis [ID6732]Technology appraisal guidanceTBC
Artificial intelligence (AI) technologies to assist histopathology for prostate cancer diagnosis [ID6684]Technology appraisal guidanceTBC
Astegolimab as add-on maintenance treatment for moderate to severe chronic obstructive pulmonary disease [ID6524]Technology appraisal guidanceTBC
Asunercept for treating glioblastoma [ID1301]Technology appraisal guidanceTBC
Atezolizumab (Tecentriq) + bevacizumab (Avastin) + chemotherapy for ovarian cancer [TSID10701]Technology appraisal guidanceTBC
Atezolizumab as neoadjuvant (with chemotherapy) and adjuvant (as monotherapy) treatment for resectable non-small-cell lung cancer [ID3894]Technology appraisal guidanceTBC
Atezolizumab for adjuvant treatment of circulating tumour DNA-positive high-risk muscle-invasive bladder cancer after cystectomy [ID6515]Technology appraisal guidanceTBC
Atezolizumab for adjuvant treatment of resected high-risk muscle-invasive urothelial cancer [ID2730]Technology appraisal guidanceTBC
Atezolizumab with BCG before surgery (neoadjuvant) for treating non-muscle-invasive bladder cancer [ID6667]Technology appraisal guidanceTBC
Atogepant for treating migraine [ID6615]Technology appraisal guidance

Results per page

  1. 10
  2. 25
  3. 50
  4. All